PROTOCOL·20 May 2026·6 min read

BPC-157 vs TB-500 — when to stack, when to pick.

Both ship in our Recovery Stack bundle for a reason. They're not redundant — they hit different mechanisms at different scales. Most healing protocols benefit from running both, but understanding why they pair is the difference between a protocol that works and a protocol that's expensive.

The short version.

BPC-157is a localised, angiogenesis-driven healing peptide — it's strongest near the injury site. Think tendon protocols, GI-tract research, ligament work. Half the literature is from rodent gastric models, and the data translates well to soft-tissue repair.

TB-500works systemically. It hits cellular actin and downstream fibroblast migration, so it doesn't need to be administered near the target tissue. Better for full-body recovery models, muscle-fibre research, scar-tissue remodelling.

Stacking them combines a localised growth-factor boost (BPC-157) with a systemic cellular-migration enabler (TB-500). That's why the Recovery Stack bundle exists. Both are research reference compounds — not for human consumption.

Side-by-side.

PropertyBPC-157TB-500

OriginFragment of human gastric juice protein (15 aa). Synthetic for research.Fragment of thymosin beta-4 (17 aa core). Synthetic for research.

Primary mechanismUpregulates growth-factor expression (VEGF, FGF) + nitric-oxide pathway; localised angiogenesis at injury site.Binds G-actin, promotes systemic actin polymerisation, fibroblast migration, anti-inflammatory cytokine modulation.

Application routeSubcutaneous near the injury site (localised research). Some labs run IM for deeper tissue.Subcutaneous anywhere — systemic effect, doesn't need to be near injury.

Half-life≈ 4 hours plasma · effects persist via local tissue uptake≈ 2 hours plasma · effects persist via systemic actin binding

Best atTendon / ligament / GI-tract repair, localised soft-tissue protocols, gastric researchSystemic recovery, muscle-fibre repair, scar-tissue remodelling, cardiovascular research

Typical research dose250–500 µg / day subcut, 2–4 week cycles2–2.5 mg twice weekly subcut, 4–6 week loading then maintenance

Variants available5 mg · 10 mg · 20 mg per vial5 mg · 10 mg · 20 mg per vial

Single-kit price (10 vials)from €69.90 (5 mg) · €119.90 (10 mg) · €189.90 (20 mg)from €79.90 (5 mg) · €139.90 (10 mg) · €229.90 (20 mg)

ReconstitutionBAC water · stable 28–42 days at 2–8 °C reconstitutedBAC water · stable 28–42 days at 2–8 °C reconstituted

Which one fits your protocol?

Pick BPC-157 alone if

· You're running a localised soft-tissue protocol — one tendon, one ligament, one well-defined injury site.
· Your research scope is GI-related (gastric ulcer models, inflammatory-bowel research).
· Budget is tight: BPC-157 is the cheaper of the two per mg at every tier.

Shop BPC-157 →

Pick TB-500 alone if

· Your model is systemic — full-body recovery, multi-site repair, cardiovascular research.
· Subject can't receive multiple near-injury injections (research-ethics, anatomy access).
· You need actin / cell-migration as the primary endpoint rather than angiogenesis.

Shop TB-500 →

Stack both if

· You want the standard recovery research protocol used in most multi-week injury-repair models.
· Localised + systemic effects compound — many protocols see faster trajectory bend at week 3–4 with both vs either alone.
· The Recovery Stack bundle saves ~10 % vs buying both separately (also includes Selank for the neurological recovery angle).

Recovery Stack bundle →

Mechanism + dosing summarised from the peer-reviewed literature. All compounds are research reference material — not for human consumption.

Questions about which to pick for your specific protocol? Email the lab.